Knee Osteoarthritis Treatment: Primary Care Practical Guide
Clinical Practice Update — Diagnosis, Non-Pharmacologic Core, Drug Selection, Injection Realities, and Surgical Referral
This is an original clinical education article informed by current guidelines and evidence. See References below for source documents.
- Clinical Focus
- Evidence-based knee osteoarthritis treatment in adults in primary care
- Target Audience
- Family physicians, general practitioners, rheumatology trainees, physiotherapists, nurse practitioners
- Setting
- Primary care, outpatient musculoskeletal clinics
- Source Evidence
- •ACR/Arthritis Foundation Guideline for OA of the Hand, Hip, and Knee (2019/2020)
- •OARSI Guidelines for Non-Surgical Management of Knee, Hip, and Polyarticular OA (2019)
- •AAOS Clinical Practice Guideline: Management of Osteoarthritis of the Knee (3rd Edition, 2021)
- •NICE Guideline NG226 — Osteoarthritis in Over 16s: Diagnosis and Management (2022)
Key Clinical Takeaways
Effective knee osteoarthritis treatment in primary care starts long before the prescription pad. Exercise, weight loss, and education are the foundations — topical agents take precedence over oral drugs, and several widely used interventions have weak or negative evidence. The rules below distil current guidance into a practical plan you can start at the first visit.
- 1Prescribe a structured exercise program to every patient with knee osteoarthritis — it is the single most effective intervention → Non-Pharmacologic Core
- 2Set a weight loss target of at least 5% in overweight patients — 10% produces disease-modifying benefit → Non-Pharmacologic Core
- 3Start topical NSAIDs as first-line drug therapy before an oral agent is considered → Pharmacotherapy
- 4Use oral NSAIDs at the lowest effective dose for the shortest necessary duration, with gastroprotection in at-risk patients → Pharmacotherapy
- 5Consider duloxetine in patients with widespread pain, centralised pain features, or comorbid depression → Pharmacotherapy
- 6Do not prescribe opioids, glucosamine, or chondroitin for chronic knee OA — evidence does not support sustained benefit → Pitfalls
- 7Offer intra-articular corticosteroid injection for acute flare relief; avoid routine hyaluronic acid injections → Injections
- 8Refer for arthroscopic debridement or meniscectomy? Do not — these procedures do not help osteoarthritis → Surgery
- 9Refer for total knee arthroplasty when pain and function fail to respond to 3–6 months of optimised conservative care → Surgery
- 10Reassess pain, function, and adherence at 3 months — and again whenever a new agent is introduced → Monitoring
Making the Diagnosis Before Starting Treatment
A clinical diagnosis is almost always enough. NICE and the ACR support diagnosing knee osteoarthritis in adults over 45 with activity-related joint pain, short-lived morning stiffness, and compatible examination findings. Imaging confirms nothing that will change management in the typical case.
Diagnose knee osteoarthritis clinically in adults aged 45 or older who report activity-related joint pain, morning stiffness under 30 minutes, and have examination findings such as crepitus, bony enlargement, or reduced range of motion. Imaging is not required to make the diagnosis.
Strong Rec High Evidence NICE NG226 ACR 2019Reserve plain radiographs for diagnostic uncertainty, suspected alternative pathology, or pre-surgical planning. The severity of radiographic findings correlates poorly with symptoms and does not guide first-line therapy.
Moderate Rec Moderate Evidence NICE NG226Screen actively for inflammatory red flags at every assessment: prolonged morning stiffness (more than 30 minutes), hot or swollen joints, systemic symptoms, involvement of the MCP or PIP joints, or night pain that wakes the patient. Any of these should prompt investigation for alternative diagnoses.
Strong Rec Moderate Evidence NICE NG226 ACR 2019Non-Pharmacologic Core of Knee Osteoarthritis Treatment
The ACR, OARSI, AAOS, and NICE agree that the foundation of knee osteoarthritis treatment is exercise, weight management, and education. Every patient should receive all three at the first visit — pharmacotherapy sits on top of this base, not in place of it.
Prescribe a structured exercise program to every patient with knee OA. Both land-based (strengthening, aerobic, neuromuscular) and aquatic exercise reduce pain and improve function. Effect sizes are comparable to oral NSAIDs without the adverse-event burden.
Strong Rec High Evidence ACR 2019 OARSI 2019 NICE NG226Set a 5–10% weight-loss target in overweight or obese patients with knee OA and offer structured weight-loss counselling. A 10% reduction in body weight produces roughly a 50% reduction in knee pain and improves joint structure on imaging.
Strong Rec High Evidence ACR 2019 OARSI 2019Refer to physical therapy for assessment, supervised exercise prescription, and self-management education. Combining physiotherapy with patient self-management programs yields better adherence and outcomes than any single intervention alone.
Strong Rec Moderate Evidence ACR 2019 NICE NG226Consider tai chi, yoga, or mind-body exercise in motivated patients — these modalities improve pain and function without the adherence drop-off seen in conventional gym-based programs, particularly in older adults.
Moderate Rec Moderate Evidence ACR 2019Comparing Non-Pharmacologic Options by Setting
| Intervention | Best Suited For | Expected Benefit | Practical Tip |
|---|---|---|---|
| Land-based exercise | All patients, any severity | Moderate pain and function gain within 8–12 weeks | Prescribe specifically — “do more walking” is not enough |
| Aquatic exercise | Severe pain, obesity, deconditioning | Similar to land-based, lower joint load | Helpful bridge when land-based is too painful |
| Weight loss (5–10%) | BMI > 25 kg/m² | Large, dose-dependent; 10% halves pain | Pair with exercise — they compound |
| Tai chi / yoga | Older adults, balance concerns | Moderate pain reduction; better adherence | Useful second-line for exercise-averse patients |
| TENS / heat / cold | Adjunct for flare or short-term relief | Small, short-lived benefit | Conditional — do not replace core therapy |
| Self-management education | All patients | Improves adherence and self-efficacy | Community programs (e.g., ESCAPE, GLA:D) are high-yield |
Pharmacotherapy in Knee Osteoarthritis Treatment
Pharmacotherapy for knee osteoarthritis treatment is about the safest effective agent, not the strongest drug available. Start topical, escalate to oral only when necessary, and revisit the risk-benefit balance at every follow-up.
Prescribe a topical NSAID (diclofenac gel 1% or 2%, applied 2–4 times daily to the affected knee) as first-line pharmacotherapy. Topicals deliver comparable analgesia to oral NSAIDs for single-joint disease with a fraction of the systemic exposure.
Strong Rec High Evidence ACR 2019 OARSI 2019 NICE NG226If an oral NSAID is needed, use the lowest effective dose for the shortest necessary duration. Consider ibuprofen 400 mg TID or naproxen 250–500 mg BID. Add gastroprotection (a proton pump inhibitor) in patients over 65, those with cardiovascular risk, or those on concomitant antiplatelet or anticoagulant therapy.
Strong Rec High Evidence ACR 2019 NICE NG226Consider duloxetine 30–60 mg daily in patients with widespread pain, centralised pain features, comorbid depression or anxiety, or inadequate response to NSAIDs. It has modest but reproducible benefit and is useful when NSAIDs are contraindicated.
Conditional Rec Moderate Evidence ACR 2019 OARSI 2019Do not prescribe opioids for chronic knee OA. The OA-specific evidence shows minimal benefit, clinically important harms (sedation, constipation, dependence, fractures in older adults), and no disease-modifying effect. If an opioid has been started for an acute flare, taper quickly.
Against High Evidence ACR 2019 OARSI 2019 NICE NG226Do not prescribe glucosamine, chondroitin, or their combinations for knee OA pain. Large high-quality trials and meta-analyses show no benefit beyond placebo. Advise interested patients honestly rather than leaving the supplement decision unaddressed.
Against High Evidence ACR 2019 OARSI 2019Drug Options at a Glance
| Drug | Typical Dose | Best Suited For | Key Cautions |
|---|---|---|---|
| Topical diclofenac | 1% or 2% gel, 2–4 times daily | First-line for localised knee OA | Local rash; wash hands after use |
| Oral ibuprofen | 400 mg TID, short courses | Flares or topical failure | GI bleeding, renal impairment, CV risk |
| Naproxen | 250–500 mg BID | CV-risk patients needing an oral NSAID | Pair with PPI in at-risk patients |
| Celecoxib | 100–200 mg daily | GI-risk patients | Use lowest dose in CV disease |
| Duloxetine | 30 mg daily, up to 60 mg | Centralised pain, NSAID-intolerant patients | Nausea, somnolence; taper on stopping |
| Paracetamol (acetaminophen) | Up to 3 g daily | Very limited role — modest short-term benefit | Hepatotoxicity; not recommended routinely by NICE |
Intra-Articular Injection Realities
Intra-articular injections occupy more clinical real estate than the evidence justifies. Understanding the actual effect sizes — and their limits — helps set honest expectations.
Offer an intra-articular corticosteroid injection for acute painful flares that fail oral or topical therapy. Expect moderate short-term pain relief lasting 4 to 8 weeks; do not promise disease modification. Limit to 3–4 injections per year per joint.
Moderate Rec Moderate Evidence ACR 2019 OARSI 2019Avoid routine use of intra-articular hyaluronic acid. Meta-analytic data do not show a clinically meaningful benefit over placebo, and the costs and visit burden are substantial. Reserve it for selected patients who have failed other options and are not surgical candidates.
Against Moderate Evidence ACR 2019 AAOS 2021Do not routinely offer platelet-rich plasma, stem cell, or prolotherapy injections for knee OA outside a clinical trial. Evidence is inconsistent and trial quality is low; commercial availability should not drive clinical use.
Against Low Evidence ACR 2019 AAOS 2021Clinical Decision Pathway
A practical, question-based sequence for the first visit and review appointments.
Surgical Referral and Total Knee Arthroplasty Timing
Total knee arthroplasty (TKA) is one of the most successful operations in medicine, but its value depends on patient selection. Refer too early and patients undergo surgery they did not yet need; refer too late and deconditioning limits their recovery.
Refer for total knee arthroplasty assessment when pain and functional limitation affect quality of life despite at least 3–6 months of optimised conservative therapy (exercise, weight management, topical and oral pharmacotherapy, and an injection where appropriate). Do not wait for radiographic end-stage disease.
Strong Rec High Evidence NICE NG226 AAOS 2021Do not refer for arthroscopic debridement, lavage, or partial meniscectomy to treat knee OA pain. Randomised trials consistently show no benefit over sham procedure or physiotherapy, with surgical risk and a prolonged recovery period.
Against High Evidence AAOS 2021 NICE NG226Counsel surgical candidates about realistic outcomes: approximately 80–90% of patients report substantial pain improvement after TKA, around 20% remain somewhat dissatisfied, and return to high-impact sport is usually not expected. Address modifiable risk factors — smoking, uncontrolled diabetes, obesity — before surgery.
Strong Rec Moderate Evidence AAOS 2021 NICE NG226Monitoring and Follow-Up
Structured follow-up keeps exercise adherence on track, catches NSAID-related adverse events, and flags escalation points early.
| Parameter | When to Check | What to Look For | Common Pitfalls |
|---|---|---|---|
| Pain and function | At 3 and 6 months | Numeric pain score, walking distance, stairs, sleep impact | Assuming stable radiographs mean stable disease |
| Exercise adherence | Every visit | Days per week, specific program, barriers | Drop-off by 3 months without reinforcement |
| Renal function and BP | Before start, 2–4 weeks, then every 6–12 months on chronic NSAIDs | Creatinine rise, new hypertension, fluid retention | Missing gradual creatinine rise in older adults |
| Weight trajectory | At 3 and 6 months if target set | Progress toward 5–10% reduction | Not linking weight gain to symptom flare |
| Mental health | When pain is out of proportion to findings | Depression, sleep disturbance, catastrophising | Treating only the joint and missing the mood |
Evidence in Context
Where the major guidelines agree, where they differ on controversial interventions, and what the most recent evidence has added.
Where ACR, OARSI, AAOS, and NICE Agree
All four guidelines converge on a small set of core points: exercise is first-line therapy, weight loss is first-line therapy in overweight patients, topical NSAIDs precede oral NSAIDs, opioids should not be prescribed for chronic OA, glucosamine and chondroitin lack meaningful benefit, and arthroscopic surgery has no role in OA-related pain. These are the safest bets in any patient encounter.
Where the Guidelines Differ
Paracetamol: ACR gives a conditional recommendation; NICE recommends against routine use. The effect size in recent trials is small and short-lived.
Hyaluronic acid injections: ACR and AAOS recommend against; OARSI gives a conditional not-recommendation. Practice continues to lag the evidence in many settings.
Intra-articular corticosteroids: Recommended as short-term therapy by ACR and OARSI, with recent imaging studies suggesting possible cartilage effects with repeated injections. Prudence, not avoidance, is the theme.
Why Exercise Is the Bedrock
Systematic reviews show that structured exercise produces pain and function improvements comparable to oral NSAIDs and better than paracetamol, with none of the cardiovascular, gastrointestinal, or renal risks. Supervised programs produce the largest effects; any movement beats none, but specificity and consistency drive results.
Weight Loss and Disease Modification
The IDEA trial and subsequent analyses suggest that combining diet and exercise to achieve around 10% weight loss produces substantially greater pain reduction than exercise alone, with imaging evidence of reduced joint loading and improved cartilage health. The newer GLP-1 receptor agonists may open additional avenues for weight-related OA management, although OA-specific trial data remain limited.
References
- 1.Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res. 2020;72(2):149–162. doi:10.1002/acr.24131
- 2.Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578–1589. doi:10.1016/j.joca.2019.06.011
- 3.NICE Guideline [NG226]. Osteoarthritis in over 16s: diagnosis and management. 2022. nice.org.uk/guidance/ng226
- 4.Brophy RH, Fillingham YA. AAOS Clinical Practice Guideline Summary: Management of Osteoarthritis of the Knee (Non-Arthroplasty), Third Edition. J Am Acad Orthop Surg. 2022;30(9):e721–e729. doi:10.5435/JAAOS-D-21-01233
- 5.Messier SP, Mihalko SL, Legault C, et al. Effects of intensive diet and exercise on knee joint loads, inflammation, and clinical outcomes among overweight and obese adults with knee osteoarthritis: the IDEA randomized clinical trial. JAMA. 2013;310(12):1263–1273. doi:10.1001/jama.2013.277669
How to Read the Evidence Tags
Every recommendation carries two tags for recommendation strength and evidence quality — Medaptly’s own simplified interpretations.
Recommendation Strength
| Tag | What It Means |
|---|---|
| Strong Rec | High-quality evidence broadly supports this action. |
| Moderate Rec | The weight of evidence favours this action. |
| Conditional Rec | The benefit is less certain — individualise based on patient factors. |
| Against | Evidence shows no benefit or potential harm. |
Evidence Quality
| Tag | What It Means |
|---|---|
| High Evidence | Multiple well-designed RCTs or high-quality meta-analyses. |
| Moderate Evidence | Single RCT or large observational studies. |
| Low Evidence | Expert consensus or small studies. |